Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) in patients with gastric adenocarcinoma

P. P. Sordillo, C. B. Magill, Richard J. Gralla, D. P. Kelsen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A phase II study of m-AMSA in patients with gastric adenocarcinoma was conducted. Twenty-three patients received m-AMSA, 90-120 mg/m2, every 3 weeks. There were no major responses among 20 evaluable patients, although one patient experienced a minor response. Depression of the white blood count was the most prominent toxicity, m-AMSA has little activity in patients with gastric adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)273-275
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume5
Issue number3
StatePublished - 1982
Externally publishedYes

Fingerprint

Amsacrine
Stomach
Adenocarcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) in patients with gastric adenocarcinoma. / Sordillo, P. P.; Magill, C. B.; Gralla, Richard J.; Kelsen, D. P.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 5, No. 3, 1982, p. 273-275.

Research output: Contribution to journalArticle

@article{cc5e885e9c66422ab0bcf21491f51e59,
title = "Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) in patients with gastric adenocarcinoma",
abstract = "A phase II study of m-AMSA in patients with gastric adenocarcinoma was conducted. Twenty-three patients received m-AMSA, 90-120 mg/m2, every 3 weeks. There were no major responses among 20 evaluable patients, although one patient experienced a minor response. Depression of the white blood count was the most prominent toxicity, m-AMSA has little activity in patients with gastric adenocarcinoma.",
author = "Sordillo, {P. P.} and Magill, {C. B.} and Gralla, {Richard J.} and Kelsen, {D. P.}",
year = "1982",
language = "English (US)",
volume = "5",
pages = "273--275",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) in patients with gastric adenocarcinoma

AU - Sordillo, P. P.

AU - Magill, C. B.

AU - Gralla, Richard J.

AU - Kelsen, D. P.

PY - 1982

Y1 - 1982

N2 - A phase II study of m-AMSA in patients with gastric adenocarcinoma was conducted. Twenty-three patients received m-AMSA, 90-120 mg/m2, every 3 weeks. There were no major responses among 20 evaluable patients, although one patient experienced a minor response. Depression of the white blood count was the most prominent toxicity, m-AMSA has little activity in patients with gastric adenocarcinoma.

AB - A phase II study of m-AMSA in patients with gastric adenocarcinoma was conducted. Twenty-three patients received m-AMSA, 90-120 mg/m2, every 3 weeks. There were no major responses among 20 evaluable patients, although one patient experienced a minor response. Depression of the white blood count was the most prominent toxicity, m-AMSA has little activity in patients with gastric adenocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0020316214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020316214&partnerID=8YFLogxK

M3 - Article

C2 - 6896259

AN - SCOPUS:0020316214

VL - 5

SP - 273

EP - 275

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -